Novartis’ Sandoz Acquires Development, Commercialization Rights to Pfizer’s Infliximab

 

Novartis AG (NYSE:NVS), a developer, manufacturer and marketer of healthcare products led by pharmaceuticals, said Friday that its generic pharmaceuticals division, Sandoz, has acquired from Pfizer (PFE) the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the 28 countries that form the European Economic Area (EEA). Infliximab is a tumor necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis (RA) and psoriasis. Under the terms of the deal, Sandoz plans to complete the clinical study program and submit the biosimilar infliximab to the European Medicines Agency (EMA) for regulatory approval and registration with the European Commission.

Subscribe to get the latest news